Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
July 07, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that...
Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
July 01, 2021 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization using computer aided drug discovery toolsAddex existing mGlu2 positive allosteric modulator, ADX71149,...
Addex Establishes At-The-Market ADS Equity Sale Program
June 30, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, June 30, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that...
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
June 29, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 17, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, June 17, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
June 07, 2021 01:00 ET
|
Addex Therapeutics
First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
Addex to Participate at the Benchmark Company Healthcare House Call Conference
May 24, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 24, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
May 17, 2021 01:00 ET
|
Addex Therapeutics
Data published in Neuropharmacology supports therapeutic role of dipraglurant in this important movement disorder Geneva, Switzerland, May 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN),...
Addex Convenes Annual General Meeting 2021
May 14, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 14, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Reports Q1 2021 Financial Results and Provides Corporate Update
May 05, 2021 01:00 ET
|
Addex Therapeutics
Strong cash and cash equivalents position at March 31, 2021 of CHF25.2M ($26.7M)Completed $11.5M fundraising in January 2021Three clinical studies in neurology programs remain on track to start during...